Pharmaceutical

Roche’s Columvi receives marketing approval in Europe

The European Commission has granted conditional marketing authorisation for Columvi to treat relapsed or refractory DLBCL in Europe.

Jul 11, 2023 - 20:00
Roche’s Columvi receives marketing approval in Europe
The European Commission has granted conditional marketing authorisation for Columvi to treat relapsed or refractory DLBCL in Europe.
Read the original article

Tags:

Previous Article

Israeli company bags $4.2m contract to develop cell therapy for radiation poisoning

Next Article

Iovance looks to advance its non-small cell lung cancer therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: More than 200 FDA staffers have retired in less than a year

STAT+: More than 200 FDA staffers have retired in less ...

Jun 6, 2023

STAT+: A breakthrough cystic fibrosis drug gave them the gift of time. But miracles come with complications.

STAT+: A breakthrough cystic fibrosis drug gave them th...

Sep 20, 2023

(Curcumin + doxorubicin) by Immix BioPharma for Triple-...

Dec 24, 2023